The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire

Imatinib mesylate, showed encouraging activity in chronic myelogenous leukemia. However, there are few data regarding his efficacy and response monitoring in Sub-Saharan African patients. Our objective was to assess response to imatinib mesylate (Glivec) in Côte d'Ivoire patients with newly dia...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Koffi, K. G., Nanho, D. C., N'dathz, E., Kouehion, P., Dissieka, R., Attia, A., Mozard, K., Tolo, A., Boidy, K., Meité, N., Ayemou, R., Sekongo, M., Tea, N., Sanogo, I.
Format: Artigo
Jezik:Inglês
Izdano: Hindawi Publishing Corporation 2010
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2938426/
https://ncbi.nlm.nih.gov/pubmed/20862197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2010/268921
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items